{{Rsnum
|rsid=2987983
|Gene=ESR2
|Chromosome=14
|position=64296935
|Orientation=minus
|GMAF=0.3907
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ESR2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 10.6 | 39.8 | 49.6
| HCB | 12.4 | 46.7 | 40.9
| JPT | 8.0 | 44.2 | 47.8
| YRI | 48.3 | 37.4 | 14.3
| ASW | 45.6 | 31.6 | 22.8
| CHB | 12.4 | 46.7 | 40.9
| CHD | 11.0 | 45.0 | 44.0
| GIH | 15.8 | 47.5 | 36.6
| LWK | 36.4 | 49.1 | 14.5
| MEX | 3.4 | 41.4 | 55.2
| MKK | 32.7 | 49.4 | 17.9
| TSI | 13.7 | 45.1 | 41.2
| HapMapRevision=28
}}
{{PMID|16921512}} In one large Swedish study, men with one or two [[rs2987983]](C) alleles were reported to be at somewhat increased (odds ratio 1.22) risk  for [[Prostate cancer]] compared to men homozygous for the wild type [[rs2987983]](T) allele, however the risk can be reduced by adding [[phytoestrogens]] to the diet.

{{PMID Auto
|PMID=19429453
|Title=Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility
}}

{{omim
|desc=ESTROGEN RECEPTOR 2; ESR2
|id=601663
|rsnum=2987983
}}

{{PharmGKB
|RSID=rs2987983
|Name_s=ESR2:rs2987983
|Gene_s=ESR2
|Feature=
|Evidence=PubMed ID:17579196
|Annotation=Haplotype tagging SNP.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145070
}}

{{PMID Auto
|PMID=20390341
|Title=A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk
}}

{{PMID Auto
|PMID=16551880
|Title=Estrogen receptor beta polymorphism is associated with prostate cancer risk.
}}

{{PMID Auto
|PMID=17935138
|Title=Haplotypes of the estrogen receptor beta gene and breast cancer risk.
|OA=1
}}

{{PMID Auto
|PMID=18304720
|Title=Estrogen receptor beta gene haplotype is associated with pelvic organ prolapse.
}}

{{PMID Auto
|PMID=18704709
|Title=Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma.
|OA=1
}}

{{PMID Auto
|PMID=19337586
|Title=Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling?
|OA=1
}}

{{PMID Auto
|PMID=19639498
|Title=Estrogen receptor beta gene polymorphisms and susceptibility to uterine fibroids.
}}

{{PMID Auto
|PMID=19654868
|Title=Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer.
|OA=1
}}

{{PMID Auto
|PMID=20215396
|Title=Genetics of hypospadias: are single-nucleotide polymorphisms in SRD5A2, ESR1, ESR2, and ATF3 really associated with the malformation?
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2987983
|overall_frequency_n=59
|overall_frequency_d=128
|overall_frequency=0.460938
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=52
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23149914
|Title=Common single-nucleotide polymorphisms in the estrogen receptor β promoter are associated with colorectal cancer survival in postmenopausal women
|OA=1
}}

{{PMID Auto
|PMID=23711151
|Title=Significance of rs1271572 in the estrogen receptor beta gene promoter and its correlation with breast cancer in a southwestern Chinese population
|OA=1
}}

{{PMID Auto
|PMID=24430361
|Title=Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India
}}

{{PMID Auto
|PMID=24881814
|Title=Polymorphisms in the promoter region of ESR2 gene and susceptibility to ovarian cancer
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}